Telmisartan, CAS number 144701-48-4, an Anti-Hypertensive research molecule, is also an approved TEVI API for compounding purposes, offered here from LGM Pharma. Indicated for the treatment of hypertension, telmisartan is known as the brand name Micardis, which is marketed by Boehringer Ingelheim Pharmaceuticals. As an angiotensin II receptor antagonist telmisartan is effective at preventing the blood vessels from narrowing, thus aiding in the heart health of patients. Patients ages 55 and older who are at risk for heart disease will particularly benefit from treatment with telmisartan. However, patients with kidney or liver disease, or patients with congenital heart failure should not be given telmisartan. The average adult patient may need two to four weeks of treatment with this antihypertensive drug before therapeutic results are apparent. Patients who receive telmisartan should be monitored on a regular basis until the efficacy of telmisartan is determined to be clinically successful.
Side effects tend to be mild, and may include sinus pain and congestion, cough, stomach and or back pain, diarrhea, headache, dizziness and a slight skin rash. The initial dose for patients is 40 milligrams taken once daily by mouth, with or without food. Maintenance doses range from 20 to 80 milligrams, also taken once daily. With the patent for Micardis set to expire in 2014, researchers are anxious to produce generic formulations of talmisartan, as the popularity and efficacy of this hypertension treatment is unmatched. Being the first drug in its class to reduce the risk of heart attack and stroke, talmisartan (Micardis) stands to be a blockbuster generic drug.
A clinical trial comparing telmisartan and carvedilol for patients with Atrial Fibrillation was published in PubMed on April 30, 2012. Conclusions from this multicenter and randomized study, completed by the Division of Cardiology at San Gennaro Hospital in Naples, Italy, were in favor of telmisartan. Significantly fewer AF episodes were reported with telmisartan compared to carvedilol, specifically 14.3 percent (telmisartan) and 37.1 percent (carvedilol). Conclusions from the study deemed telmisartan more effective than carvedilol in the prevention of recurrent episodes of atrial fibrillation.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.